Axel Hauschild

发表

Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task.

Achim Hekler, Carola Berking, Dirk Schadendorf, 2019, European journal of cancer.

Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark.

Achim Hekler, Carola Berking, Dirk Schadendorf, 2019, European journal of cancer.

A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task.

Achim Hekler, Carola Berking, Dirk Schadendorf, 2019, European journal of cancer.

Superior skin cancer classification by the combination of human and artificial intelligence.

Tim Holland-Letz, Achim Hekler, Carola Berking, 2019, European journal of cancer.

Diagnosis and treatment of melanoma . European consensus-based interdisciplinary guideline e Update 2016

Josep Malvehy, Axel Hauschild, Jean-Jacques Grob, 2016 .

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.

Giovanni Pellacani, Josep Malvehy, Axel Hauschild, 2019, European journal of cancer.

Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data.

Carola Berking, Wiebke Sondermann, Dirk Schadendorf, 2019, European journal of cancer.

Deep neural networks are superior to dermatologists in melanoma image classification.

Tim Holland-Letz, Achim Hekler, Jochen S. Utikal, 2019, European journal of cancer.

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

Dirk Schadendorf, Alessandro Testori, Axel Hauschild, 2014, The Lancet. Oncology.

Melanomas of unknown primary frequently harbor TERT-promoter mutations

Sandra Krüger, Axel Hauschild, Jochen Haag, 2014, Melanoma research.

Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.

Dirk Schadendorf, Axel Hauschild, Reinhard Dummer, 2014, European journal of cancer.

Melanoma in 2013: Melanoma—the run of success continues

Dirk Schadendorf, Axel Hauschild, A. Hauschild, 2014, Nature Reviews Clinical Oncology.

Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.

Josep Malvehy, Axel Hauschild, Jean-Jacques Grob, 2012, European journal of cancer.

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Axel Hoos, Alessandro Testori, Axel Hauschild, 2011, The New England journal of medicine.

Novel DNA methylation markers with potential prognostic relevance in advanced malignant melanoma identified using COBRA assays

Axel Hauschild, Hannes-Friedrich Ulbrich, A. Hauschild, 2015, Melanoma research.

Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline.

Josep Malvehy, Axel Hauschild, Jean-Jacques Grob, 2010, European journal of cancer.

Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha‐2b in metastatic melanoma (phase II DeCOG trial)

Axel Hauschild, Michael Weichenthal, Claus Garbe, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Melanoma

Carola Berking, Dirk Schadendorf, Alexander Roesch, 2018, The Lancet.

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.

Dirk Schadendorf, Axel Hauschild, Antoni Ribas, 2019, European journal of cancer.

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

Aleksandar Sekulic, Michael R Migden, Axel Hauschild, 2012, The New England journal of medicine.